US-based Becton, Dickinson and Co (BD) has announced seven underwritten public offerings of notes to raise $10.463bn.

The notes carry interest rates of 0.368% (due June 2019), 2.133% (due June 2019), and 2.404% (due June 2020). They also have rates of 2.894% (due June 2022), floating rate (due June 2022), 3.363% (due June 2024), 3.700% (due June 2027), and 4.669% (due June 2047).

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Earlens Corp has announced the private placement of Series C preferred stock in order to raise $73m.

Vertex Healthcare subscribed to the placement along with participation from Cochlear Ltd, CRG, Richard King Mellon Foundation, Windham Venture Partners, and others.

The US-based company plans to use the funds for commercialisation of its Earlens hearing aid, and to support research and development (R&D) activities.

The UK-based biopharmaceutical company AstraZeneca plc has announced three public offerings of senior notes, including floating rate senior notes to raise gross proceeds of $2bn.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The notes bear interest rates of 2.375% and 3.125%, which are due to mature in 2022 and 2027, respectively.

"The US-based company plans to use the funds for commercialisation of its Earlens hearing aid, and to support research and development (R&D) activities."

AstraZeneca plans to use the funds for general corporate purposes.

2bPrecise LLC has signed a technology licensing agreement with non-profit medical research group, Mayo Clinic, to develop genomics-based clinical decision support protocols.

As part of the agreement, 2bPrecise will incorporate the new protocols to measure results in patients affected with cardiovascular genetic disease.

2bPrecise is a provider of cloud-based precision medicine platform and is based in the US.

Trice Medical Inc has announced the raising of $19.3m in a series C venture financing round.

The US-based orthopaedic diagnostics devices developer plans to use the funds to expand its presence in the US market.